Novel bioabsorbable polymer and polymer-free metallic drug-eluting stents

Jason Nogic, Liam M. McCormick, Rohin Francis, Nitesh Nerlekar, Catherine Jaworski, Nick E.J. West, Adam J. Brown

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

The introduction of drug-eluting stents (DES) significantly reduced angiographic restenosis and the clinical need for revascularization following percutaneous coronary intervention. However, concerns remain regarding the long-term safety and efficacy of DES. The use of durable polymers for drug elution that have limited biocompatibility is thought to contribute toward DES failure, by promoting an adverse local inflammatory response and vascular toxicity. Biodegradable polymer and polymer-free metallic stents represent two novel technological solutions to this challenging clinical problem. This review summarizes the available clinical evidence supporting the use of either biodegradable polymer or polymer-free DES platforms.

Original languageEnglish
Pages (from-to)435-443
Number of pages9
JournalJournal of Cardiology
Volume71
Issue number5
DOIs
Publication statusPublished - 1 May 2018

Keywords

  • Biodegradable polymer
  • Coronary artery disease
  • Drug-eluting stents
  • Percutaneous coronary intervention
  • Polymer-free

Cite this

Nogic, Jason ; McCormick, Liam M. ; Francis, Rohin ; Nerlekar, Nitesh ; Jaworski, Catherine ; West, Nick E.J. ; Brown, Adam J. / Novel bioabsorbable polymer and polymer-free metallic drug-eluting stents. In: Journal of Cardiology. 2018 ; Vol. 71, No. 5. pp. 435-443.
@article{b894fb24e67b471594d0a3066940c985,
title = "Novel bioabsorbable polymer and polymer-free metallic drug-eluting stents",
abstract = "The introduction of drug-eluting stents (DES) significantly reduced angiographic restenosis and the clinical need for revascularization following percutaneous coronary intervention. However, concerns remain regarding the long-term safety and efficacy of DES. The use of durable polymers for drug elution that have limited biocompatibility is thought to contribute toward DES failure, by promoting an adverse local inflammatory response and vascular toxicity. Biodegradable polymer and polymer-free metallic stents represent two novel technological solutions to this challenging clinical problem. This review summarizes the available clinical evidence supporting the use of either biodegradable polymer or polymer-free DES platforms.",
keywords = "Biodegradable polymer, Coronary artery disease, Drug-eluting stents, Percutaneous coronary intervention, Polymer-free",
author = "Jason Nogic and McCormick, {Liam M.} and Rohin Francis and Nitesh Nerlekar and Catherine Jaworski and West, {Nick E.J.} and Brown, {Adam J.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.jjcc.2017.12.007",
language = "English",
volume = "71",
pages = "435--443",
journal = "Journal of Cardiology",
issn = "0914-5087",
publisher = "Elsevier",
number = "5",

}

Novel bioabsorbable polymer and polymer-free metallic drug-eluting stents. / Nogic, Jason; McCormick, Liam M.; Francis, Rohin; Nerlekar, Nitesh; Jaworski, Catherine; West, Nick E.J.; Brown, Adam J.

In: Journal of Cardiology, Vol. 71, No. 5, 01.05.2018, p. 435-443.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Novel bioabsorbable polymer and polymer-free metallic drug-eluting stents

AU - Nogic, Jason

AU - McCormick, Liam M.

AU - Francis, Rohin

AU - Nerlekar, Nitesh

AU - Jaworski, Catherine

AU - West, Nick E.J.

AU - Brown, Adam J.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - The introduction of drug-eluting stents (DES) significantly reduced angiographic restenosis and the clinical need for revascularization following percutaneous coronary intervention. However, concerns remain regarding the long-term safety and efficacy of DES. The use of durable polymers for drug elution that have limited biocompatibility is thought to contribute toward DES failure, by promoting an adverse local inflammatory response and vascular toxicity. Biodegradable polymer and polymer-free metallic stents represent two novel technological solutions to this challenging clinical problem. This review summarizes the available clinical evidence supporting the use of either biodegradable polymer or polymer-free DES platforms.

AB - The introduction of drug-eluting stents (DES) significantly reduced angiographic restenosis and the clinical need for revascularization following percutaneous coronary intervention. However, concerns remain regarding the long-term safety and efficacy of DES. The use of durable polymers for drug elution that have limited biocompatibility is thought to contribute toward DES failure, by promoting an adverse local inflammatory response and vascular toxicity. Biodegradable polymer and polymer-free metallic stents represent two novel technological solutions to this challenging clinical problem. This review summarizes the available clinical evidence supporting the use of either biodegradable polymer or polymer-free DES platforms.

KW - Biodegradable polymer

KW - Coronary artery disease

KW - Drug-eluting stents

KW - Percutaneous coronary intervention

KW - Polymer-free

UR - http://www.scopus.com/inward/record.url?scp=85040447075&partnerID=8YFLogxK

U2 - 10.1016/j.jjcc.2017.12.007

DO - 10.1016/j.jjcc.2017.12.007

M3 - Review Article

VL - 71

SP - 435

EP - 443

JO - Journal of Cardiology

JF - Journal of Cardiology

SN - 0914-5087

IS - 5

ER -